Tilray Brands (TLRY) News
Latest news and analysis
Tilray Accelerates Medical Cannabis Expansion Despite Sector Headwinds
TLRY pushes international medical platform growth as cannabis stocks face regulatory uncertainty and market volatility
Tilray's Panama Push Tests International Cannabis Expansion Strategy
TLRY explores Central American operations as cannabis companies seek growth beyond saturated North American markets amid regulatory headwinds.
Tilray Stock Eyes Inflection Point as Cannabis Markets Shift
TLRY approaches critical juncture amid evolving regulatory landscape and operational restructuring efforts across North American cannabis markets.
TLRY Diversifies Beyond Cannabis With Craft Beverage Expansion
Tilray Brands leverages dual-market strategy combining cannabis operations with craft beverage acquisitions to drive revenue growth and market expansion.
Tilray Positioned for US Cannabis Rescheduling Windfall
TLRY stock could surge as federal rescheduling opens massive US market opportunities for the Canadian cannabis giant's established operations.
Tilray's Medical Cannabis Pivot Tests Investor Patience
TLRY explores medical cannabis expansion as recreational revenues plateau. Market questions execution amid regulatory headwinds.
Tilray's HelloMD Buy Targets Digital Cannabis Market Growth
TLRY acquires telemedicine platform to expand digital footprint and capture growing online cannabis consultation market ahead of broader legalization.
Tilray Accelerates International Expansion as Cannabis Markets Mature
TLRY pushes aggressive global growth strategy amid consolidating cannabis sector, targeting European medical markets and international partnerships.
Tilray Brands Surges 6% as Volume Spikes Amid Market Recovery
TLRY shares jumped to $4.76 on elevated trading volume of nearly 700K shares as the cannabis giant shows signs of momentum.
Tilray's Medical Cannabis Push Tests Investor Patience Amid Weak Fundamentals
TLRY's medical expansion strategy faces scrutiny as investors weigh growth potential against persistent losses and regulatory headwinds in key markets.